Clinical Trial Detail

NCT ID NCT02654587
Title Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors OSE Immunotherapeutics

lung non-small cell carcinoma


OSE 2101

Docetaxel + Pemetrexed

Age Groups: adult

Additional content available in CKB BOOST